System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Richard Greil, MD

Oncology — Paracelsus Medical University, Austria

LeadR Profile

Prof Richard Greil, MD Paracelsus Medical University Austria
5 345 ScienceLeadR Reputation 5345

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1989 - 2026
Source: PubMed

Paracelsus Medical University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1250

Citations

Citations: 81 451 1st author: 39 Last author: 252 Unique author: 10

Main journals

Blood 182
J Clin Oncol 136
Ann Oncol 92
Cancer Res 67
N Engl J Med 35

Best Journals

J Clin Oncol 43
Ann Oncol 36
N Engl J Med 35

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Validation of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI) in the GHSG HD21 trial.
hodgkin disease, lymphoma		Hemasphere20260
Central nervous system metastases in metastatic breast cancer: Incidence, subtype-specific patterns, and outcomes from the Austrian AGMT_MBC registry.
registries, radiotherapy, breast neoplasms, incidence, brain, neoplasms, central nervous system, neoplasm metastasis, breast, diagnosis, therapeutics, nervous system		Breast20260
The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer.
genes, lymph nodes, breast neoplasms, neoplasms, lymph, breast		Clin Breast Cancer20260
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series.
cells, lymphoma, cytokine release syndrome, lymphoma, mantle-cell, therapeutics		EJHaem20260
Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.
safety, neoplasms, therapeutics, medical oncology, cholangiocarcinoma		J Clin Oncol Top journal20263

Clinical Studies 123

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 3 73
Phase 2 24
N/A 14
Phase 1/Phase 2 5
Phase 1 4
Phase 2/Phase 3 3

By status:

Completed 89
Active not recruiting 17
Terminated 6
Recruiting 5
Unknown 4
No longer available 2

By type:

Interventional 113
Observational 8
Expanded Access 2

By Monocentric/Multicentric:

monocentric 20
multicentric2to4 3
multicentric5to9 10
multicentricup10 90

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
NCT06678919 — registries, neoplasms, therapeutics, colorectal neoplasms		N/ARecruiting2024
AGMT Austrian Lymphoma Registry
NCT06294652 — registries, cells, lymphocytes, hodgkin disease, lymphoma, lymphoma, large b-cell, diffuse, lymph, prognosis		N/ARecruiting2024
LUNAR 2 TTFields With Pembrolizumab Platinum based Chemotherapy for Metastatic NSCLC
NCT06216301 — cells, lung, neoplasms, transducers, immunogenic cell death, carcinoma, non-small-cell lung, drug therapy, immune checkpoint inhibitors, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, immune system, therapeutics, cell death, cell division, chemotherapy, carcinoma		Phase 3Recruiting2024
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B cell Lymphoma Ineligible for R CHOP
NCT05798156 — cells, epitopes, lymphoma, b-cell, pharmaceutical preparations, lymphoma, lymphoma, large b-cell, diffuse, drug therapy, rituximab, peptide hydrolases, antibodies, monoclonal, b-lymphocytes, chemotherapy		Phase 2Active not recruiting2023
A Study to Learn About a New Medicine Called Vepdegestrant (ARV 471 PF 07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623 — fulvestrant, estrogens, breast neoplasms, receptors, estrogen, neoplasms, anti-retroviral agents, hormones, breast, therapeutics		Phase 3Active not recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS